180 related articles for article (PubMed ID: 36069781)
41. Protocol for Take-home naloxone In Multicentre Emergency (TIME) settings: feasibility study.
Jones M; Bell F; Benger J; Black S; Buykx P; Dixon S; Driscoll T; Evans B; Edwards A; Fuller G; Goodacre S; Hoskins R; Hughes J; John A; Jones J; Moore C; Sampson F; Watkins A; Snooks H
Pilot Feasibility Stud; 2020; 6():96. PubMed ID: 32670598
[TBL] [Abstract][Full Text] [Related]
42. Personal experience and awareness of opioid overdose occurrence among peers and willingness to administer naloxone in South Africa: findings from a three-city pilot survey of homeless people who use drugs.
Wilson M; Brumwell A; Stowe MJ; Shelly S; Scheibe A
Harm Reduct J; 2022 Feb; 19(1):17. PubMed ID: 35148779
[TBL] [Abstract][Full Text] [Related]
43. Amount of naloxone used to reverse opioid overdoses outside of medical practice in a city with increasing illicitly manufactured fentanyl in illicit drug supply.
Bell A; Bennett AS; Jones TS; Doe-Simkins M; Williams LD
Subst Abus; 2019; 40(1):52-55. PubMed ID: 29558283
[No Abstract] [Full Text] [Related]
44. Using ADAPT-ITT framework to tailor evidence-based interventions for addressing methamphetamine use among methadone patients in Vietnam.
Giang LM; Trang NT; Thuy DT; Nguyen HH; Diep NB; Van HTH; Truc TT; Reback CJ; Li M; Van Dung D; Shoptaw S
Drug Alcohol Rev; 2023 Nov; 42(7):1667-1679. PubMed ID: 37614129
[TBL] [Abstract][Full Text] [Related]
45. The Opioid Crisis: Prevalence and Markets of Opioids.
Gardner EA; McGrath SA; Dowling D; Bai D
Forensic Sci Rev; 2022 Jan; 34(1):43-70. PubMed ID: 35105535
[TBL] [Abstract][Full Text] [Related]
46. Community-Based Cluster-Randomized Trial to Reduce Opioid Overdose Deaths.
; Samet JH; El-Bassel N; Winhusen TJ; Jackson RD; Oga EA; Chandler RK; Villani J; Freisthler B; Adams J; Aldridge A; Angerame A; Babineau DC; Bagley SM; Baker TJ; Balvanz P; Barbosa C; Barocas J; Battaglia TA; Beard DD; Beers D; Blevins D; Bove N; Bridden C; Brown JL; Bush HM; Bush JL; Caldwell R; Calver K; Calvert D; Campbell ANC; Carpenter J; Caspar R; Chassler D; Chaya J; Cheng DM; Cunningham CO; Dasgupta A; David JL; Davis A; Dean T; Drainoni ML; Eggleston B; Fanucchi LC; Feaster DJ; Fernandez S; Figueroa W; Freedman DA; Freeman PR; Freiermuth CE; Friedlander E; Gelberg KH; Gibson EB; Gilbert L; Glasgow L; Goddard-Eckrich DA; Gomori S; Gruss DE; Gulley J; Gutnick D; Hall ME; Harger Dykes N; Hargrove SL; Harlow K; Harris A; Harris D; Helme DW; Holloway J; Hotchkiss J; Huang T; Huerta TR; Hunt T; Hyder A; Ingram VL; Ingram T; Kauffman E; Kimball JL; Kinnard EN; Knott C; Knudsen HK; Konstan MW; Kosakowski S; Larochelle MR; Leaver HM; LeBaron PA; Lefebvre RC; Levin FR; Lewis N; Lewis N; Lofwall MR; Lounsbury DW; Luster JE; Lyons MS; Mack A; Marks KR; Marquesano S; Mauk R; McAlearney AS; McConnell K; McGladrey ML; McMullan J; Miles J; Munoz Lopez R; Nelson A; Neufeld JL; Newman L; Nguyen TQ; Nunes EV; Oller DA; Oser CB; Oyler DR; Pagnano S; Parran TV; Powell J; Powers K; Ralston W; Ramsey K; Rapkin BD; Reynolds JG; Roberts MF; Robertson W; Rock P; Rodgers E; Rodriguez S; Rudorf M; Ryan S; Salsberry P; Salvage M; Sabounchi N; Saucier M; Savitzky C; Schackman B; Schady E; Seiber EE; Shadwick A; Shoben A; Slater MD; Slavova S; Speer D; Sprunger J; Starbird LE; Staton M; Stein MD; Stevens-Watkins DJ; Stopka TJ; Sullivan A; Surratt HL; Sword Cruz R; Talbert JC; Taylor JL; Thompson KL; Vandergrift N; Vickers-Smith RA; Vietze DJ; Walker DM; Walley AY; Walters ST; Weiss R; Westgate PM; Wu E; Young AM; Zarkin GA; Walsh SL
N Engl J Med; 2024 Jun; ():. PubMed ID: 38884347
[TBL] [Abstract][Full Text] [Related]
47. Overdoses due to fentanyl and its analogues (F/FAs) push naloxone to the limit.
Pergolizzi JV; Dahan A; Ann LeQuang J; Raffa RB
J Clin Pharm Ther; 2021 Dec; 46(6):1501-1504. PubMed ID: 34111307
[TBL] [Abstract][Full Text] [Related]
48. Prepacked naloxone administration for suspected opioid overdose in the era of illicitly manufactured fentanyl: a retrospective study of regional poison center data.
Mahonski SG; Leonard JB; Gatz JD; Seung H; Haas EE; Kim HK
Clin Toxicol (Phila); 2020 Feb; 58(2):117-123. PubMed ID: 31092050
[No Abstract] [Full Text] [Related]
49. Distribution of take-home opioid antagonist kits during a synthetic opioid epidemic in British Columbia, Canada: a modelling study.
Irvine MA; Buxton JA; Otterstatter M; Balshaw R; Gustafson R; Tyndall M; Kendall P; Kerr T; Gilbert M; Coombs D
Lancet Public Health; 2018 May; 3(5):e218-e225. PubMed ID: 29678561
[TBL] [Abstract][Full Text] [Related]
50. "It's my frenemy": A qualitative exploration of knowledge and perceptions of fentanyl use during the COVID-19 pandemic in people who use drugs at a syringe services program in Philadelphia, PA.
Bass SB; Kelly PJA; Pandit-Kerr S; Pilla J; Morris K; Larsen E; Wisdom JP; Torralva PR
Front Public Health; 2022; 10():882421. PubMed ID: 35937263
[TBL] [Abstract][Full Text] [Related]
51. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
52. Using Social Media to Examine Themes Surrounding Fentanyl Misuse and Risk Indicators.
Kasson E; Filiatreau LM; Kaiser N; Davet K; Taylor J; Garg S; El Sherief M; Aledavood T; De Choudhury M; Cavazos-Rehg P
Subst Use Misuse; 2023; 58(7):920-929. PubMed ID: 37021375
[No Abstract] [Full Text] [Related]
53. Pharmaceutical opioid poisonings in Victoria, Australia: Rates and characteristics of a decade of emergency department presentations among nine pharmaceutical opioids.
Lam T; Hayman J; Berecki-Gisolf J; Sanfilippo P; Lubman DI; Nielsen S
Addiction; 2022 Mar; 117(3):623-636. PubMed ID: 34338377
[TBL] [Abstract][Full Text] [Related]
54. Fourth Wave of Opioid (Illicit Drug) Overdose Deaths and Diminishing Access to Prescription Opioids and Interventional Techniques: Cause and Effect.
Manchikanti L; Singh VM; Staats PS; Trescot AM; Prunskis J; Knezevic NN; Soin A; Kaye AD; Atluri S; Boswell MV; Abd-Elsayed A; Hirsch JA
Pain Physician; 2022 Mar; 25(2):97-124. PubMed ID: 35322965
[TBL] [Abstract][Full Text] [Related]
55. "If I had them, I would use them every time": Perspectives on fentanyl test strip use from people who use drugs.
Reed MK; Salcedo VJ; Guth A; Rising KL
J Subst Abuse Treat; 2022 Sep; 140():108790. PubMed ID: 35577663
[TBL] [Abstract][Full Text] [Related]
56. Impacts of an opioid overdose prevention intervention delivered subsequent to acute care.
Banta-Green CJ; Coffin PO; Merrill JO; Sears JM; Dunn C; Floyd AS; Whiteside LK; Yanez ND; Donovan DM
Inj Prev; 2019 Jun; 25(3):191-198. PubMed ID: 29436397
[TBL] [Abstract][Full Text] [Related]
57. 'I have it just in case' - Naloxone access and changes in opioid use behaviours.
Heavey SC; Chang YP; Vest BM; Collins RL; Wieczorek W; Homish GG
Int J Drug Policy; 2018 Jan; 51():27-35. PubMed ID: 29156400
[TBL] [Abstract][Full Text] [Related]
58. "They say it's fentanyl, but they honestly look like Perc 30s": Initiation and use of counterfeit fentanyl pills.
Daniulaityte R; Sweeney K; Ki S; Doebbeling BN; Mendoza N
Harm Reduct J; 2022 May; 19(1):52. PubMed ID: 35614447
[TBL] [Abstract][Full Text] [Related]
59. Opioid agonist treatment and risk of mortality during opioid overdose public health emergency: population based retrospective cohort study.
Pearce LA; Min JE; Piske M; Zhou H; Homayra F; Slaunwhite A; Irvine M; McGowan G; Nosyk B
BMJ; 2020 Mar; 368():m772. PubMed ID: 32234712
[TBL] [Abstract][Full Text] [Related]
60. Opioid Overdose Education for Individuals Prescribed Opioids for Pain Management: Randomized Comparison of Two Computer-Based Interventions.
Huhn AS; Garcia-Romeu AP; Dunn KE
Front Psychiatry; 2018; 9():34. PubMed ID: 29483884
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
